CAMBRIDGE, Massachusetts, July 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic ...
Everyday Health on MSN
What people of color should know about joining an atopic dermatitis clinical trial
Learn why representation in atopic dermatitis clinical trials matters for people of color, as well as the benefits, risks, and questions to ask before enrolling.
Add Yahoo as a preferred source to see more of our stories on Google. QuantalX's Delphi-MD is intended to help clinicians gain an understanding of brain function to make better-informed decisions ...
The remedy phase of Google’s ad-tech antitrust trial begins today, following the company’s loss in April when the court ruled that Google maintained monopolies in the open web display publisher ad ...
A French regulator’s attempt to open ad tech competition failed. Equativ CEO Arnaud Creput testified the French order “had no impact at all” on publisher ad server competition. That was partially ...
WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory ...
TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence ...
CNBC’s MacKenzie Sigalos joins 'Money Movers' to discuss Google's ad tech trial strategy as the company moves into an AI advertising war. Got a confidential news tip? We want to hear from you. Sign up ...
The remedy phase of Google’s ad-tech antitrust trial begins today. At the end of it, Google will find out its fate in this trial. As a reminder, Google did lose the ad-tech trial, so the only thing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results